- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
X-GEN receives approval for drug
X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.
Key Points
Big Flats, NY-X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma, secondary glaucoma, and preoperative use for the treatment of acute angle-closure glaucoma.
A commercially available brand is equivalent (Diamox, Duramed Pharmaceuticals), according to the company. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide in the form a sterile, preservative-free lyophilized powder.
"Currently, there is only one supplier of acetazolamide for injection USP," said Susan Badia, X-GEN president and chief executive officer. "Our launch of this product will ensure consistent supply and steady, competitive price levels."
